J. R. Bianchine, M.D.; M. J. T. Peaston, M.D.
This content is PDF only. Please click on the PDF icon to access.
The therapeutic efficacy of large oral doses of L-3:4 dihydroxyphenylalanine (DOPA) in selected patients with Parkinson's disease has been made clear by Cotzias and others. The purpose of this study is to determine the metabolic fate of orally administered L-DOPA. Six men with uncomplicated Parkinson's disease were selected for study. All patients were hospitalized and fasted overnight prior to study. A gelatin capsule containing 100 µc L-[C14]-DOPA (Hoffman-La Roche) labelled in beta position and a total of 500 mg L-DOPA were administered orally at time zero. Serum, expired air, urine, and stool were sampled, first at hourly, then at longer
Learn more about subscription options.
Register Now for a free account.
Bianchine JR, Peaston MJT. Metabolism of Orally Administered L-(C14)-DOPA in Patients with Parkinson's Disease.. Ann Intern Med. 1970;72:806. doi: 10.7326/0003-4819-72-5-806_1
Download citation file:
Published: Ann Intern Med. 1970;72(5):806.
Copyright © 2017 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only